妥布霉素地塞米松治疗睑板腺功能障碍的临床观察  

Clinical Observation of Tobramycin Dexamethasone in the Treatment of Meibomian Gland Dysfunction

作　　者：丁剑锋[1] 罗远湘[1] 李璐[1] 

机构地区：[1]新疆石河子大学第一附属医院眼科,新疆石河子832000

出　　处：《中国药房》2017年第15期2060-2062,共3页China Pharmacy

摘　　要：目的:观察妥布霉素地塞米松治疗睑板腺功能障碍(MGD)的疗效和安全性。方法:108例MGD患者随机分为对照组(53例)和观察组(55例)。对照组患者给予常规物理清洁方式清理眼睑,同时饭后温水送服盐酸多西环素片0.1 g,每日2次。观察组患者在对照组治疗的基础上给予妥布霉素地塞米松眼膏长约1.0~1.5 cm,涂入结膜囊,每日4次。两组疗程均为4周。观察两组患者的临床疗效,治疗前后眼睑观察评分、症状评分、白细胞介素6(IL-6)和肿瘤坏死因子α(TNF-α)水平及不良反应发生情况。结果:观察组患者总有效率显著高于对照组(89.1%vs.77.4%),差异有统计学意义(P<0.05)。治疗前,两组患者眼睑观察评分、症状评分、IL-6和TNF-α水平比较,差异均无统计学意义(P>0.05)。治疗后,两组患者眼睑观察评分均显著高于同组治疗前,且观察组显著高于对照组;两组患者症状评分、IL-6和TNF-α水平均显著低于同组治疗前,且观察组显著低于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:在常规治疗的基础上给予妥布霉素地塞米松治疗MGD患者的疗效显著,可显著改善临床症状,且未增加不良反应的发生。OBJECTIVE： To observe therapeutic efficacy and safety of tobramycin dexamethasone in the treatment of meibo- mian gland dysfunction （MGD）. METHODS： 108 MGD patients were randomly divided into control group （53 cases） and observa- tion group （55 cases）. Control group was given eyelid cleaning with conventional physical cleaning method, at the same time, giv- en Doxyeycline hydrochloride tablets 0.1 g orally after meal, twice a day. Based on control group, observation group was addition- ally given Tobramycin and dexamethasone eye ointment with length of 1.0-1.5 cm, smearing into conjunctival sac, 4 times a day. Treatment courses of 2 groups lasted for 4 weeks. Clinical efficacies of 2 groups were observed as well as eyelid observation score, symptom score, the levels of IL-6 and TNF-α, the occurrence of ADR before and after treatment. RESULTS： The total response rate of observation group was significantly higher than that of control group（89.1% vs. 77,4% ）, with statistical significance （P〈 0.05）. Before treatment, there was no statistical significance in eyelid observation score, symptom score, the levels of IL-6 and TNF-α between 2 groups （P〉0.05）. After treatment, eyelid observation score of 2 groups were significantly higher than before treatment, and the observation group was significantly higher than the control group; symptom score and the levels of IL-6 and TNF-α in 2 groups were significantly lower than before treatment, and the observation group was significantly lower than the con- trol group, with statistical significance （P〈0.05）.There was no statistical significance in the incidence of ADR between 2 groups （P〉0.05）. CONCLUSIONS： Based on routine treatment, tobramycin dexamethasone shows significant therapeutic efficacy for MGD, and can improve clinical symptoms significantly but does not increase the occurrence of ADR.

关 键 词：妥布霉素地塞米松 睑板腺功能障碍 疗效 安全性 白细胞介素6 肿瘤坏死因子Α 

分 类 号：R777.1[医药卫生—眼科]